Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sunshine Biopharma Inc. - Common stock (NQ:SBFM)

0.4201 -0.2464 (-36.97%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sunshine Biopharma Inc. - Common stock

< Previous 1 2 3 Next >
News headline image
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgery Global ondansetron market projected to reach $2.98 billion by... 
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activity Significant dose-dependent suppression of pulmonary viral replication in vivo Strong oral bioavailability and... 
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
Via ACCESS Newswire
News headline image
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
Via ACCESS Newswire
News headline image
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
Via ACCESS Newswire
News headline image
Stocks to Watch: NDRA, SBFM, GOVX, HIVE, ANY Trading Actively NOW!
Via AB Newswire
Topics Artificial Intelligence
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Beats Q1 Expectations, TAEUS® Liver Imaging Advances and Strategic Review Acceleration Fuels Investor Awareness
Via AB Newswire
News headline image
Stocks Under $1: NXXT, TOON, VRAX, AIM, SBFM on Breakout Watch
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
Via ACCESS Newswire
BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Closes $6 Million Public Offering
Via Investor Brand Network
News headline image
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
Via ACCESS Newswire
News headline image
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
Via ACCESS Newswire
News headline image
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
Via ACCESS Newswire
News headline image
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
Via ACCESS Newswire
News headline image
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin
Via ACCESS Newswire
News headline image
Sunshine Biopharma Stock is 34% Higher Since September as Investors Reward Performance Combined with Innovation (NASDAQ: SBFM)
Via AB Newswire
News headline image
Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)
Via ACCESS Newswire
News headline image
Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)
Via ACCESS Newswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.